Puma Biotechnology Revenue and Competitors
Estimated Revenue & Valuation
- Puma Biotechnology's estimated annual revenue is currently $250.4M per year.
- Puma Biotechnology's estimated revenue per employee is $962,923
- Puma Biotechnology's total funding is $809.3M.
- Puma Biotechnology's current valuation is $107.1M. (January 2022)
Employee Data
- Puma Biotechnology has 260 Employees.
- Puma Biotechnology grew their employee count by 5% last year.
Puma Biotechnology's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Sr VP, Clinical Operations | Reveal Email/Phone |
2 | Chief Accounting Officer | Reveal Email/Phone |
3 | Sr. VP, Finance & Administration/Treasurer | Reveal Email/Phone |
4 | VP Sales | Reveal Email/Phone |
5 | VP Commercial Analytics and Operations | Reveal Email/Phone |
6 | Head Information Technology | Reveal Email/Phone |
7 | VP, Marketing | Reveal Email/Phone |
8 | VP FP&A | Reveal Email/Phone |
9 | SVP, Supply Chain and Manufacturing | Reveal Email/Phone |
10 | VP R&D Quality Assurance | Reveal Email/Phone |
Puma Biotechnology Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Puma Biotechnology?
Puma Biotechnology, Inc. is a development-stage biopharmaceutical company dedicated to in-licensing and developing novel therapeutics for the treatment of cancer. Our strategy is to license technologies that have previously been tested in clinical trials, enabling us to obtain an initial indication of the drug's safety and biological activity in humans before committing capital to the drug's development.
keywords:N/A
$809.3M
Total Funding
260
Number of Employees
$250.4M
Revenue (est)
5%
Employee Growth %
$107.1M
Valuation
N/A
Accelerator
Puma Biotechnology News
Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the...
Puma Biotechnology Announces Publication of Neratinib Abstract Titles for the 2022 ASCO Annual Meeting. April 27, 2022 04:15 PM Eastern Daylight...
LOS ANGELES, April 21, 2022--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that it has entered into a note purchase agreement with a fund of Athyrium Capital Management, LP, a specialized asset management company focused on opportunities in the global healthcare sector, for the issuance of ...
LOS ANGELES und CASTRES (Frankreich)--(BUSINESS WIRE)--Feb 27, 2021-- Das Biopharmaunternehmen Puma Biotechnology, Inc. (Nasdaq: PBYI), und das namhafte französische Pharmaunternehmen Pierre Fabre haben eine Verlängerung der Lizenzvereinbarung von 2019 vereinbart, die Pierre Fabre die exklusive ...
Other Companies in Los Angeles
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $60.1M | 260 | -2% | N/A |
#2 | $65.2M | 260 | 73% | N/A |
#3 | $57.5M | 261 | 0% | $150M |
#4 | $92.7M | 261 | 15% | N/A |
#5 | $60.3M | 261 | 9% | N/A |